Vakcina Kft.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vakcina Kft.
In HIV Research, A Race For The Cure Is Back On Track
Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.
2011 Scrip 100: All to play for as new technologies shake up the vaccines market
New antigen types, novel delivery systems and a shift away from the low-hanging fruit towards more problematic conditions point to healthy prospects in the vaccines space, writes Dr Peter Charlish.
Selecta raises "opportunistic" financing for nanoparticle vaccine development
Selecta Biosciences has raised $15 million in an "opportunistic" series C financing. OrbiMed Advisors led the round, with existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments also participating.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Vaccine Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice